

# CONFERENCE PROGRAM

## Saturday, October 7

3:00 p.m.-7:00 p.m.

**REGISTRATION**

6:00 p.m.-7:30 p.m.

**WELCOME AND KEYNOTE LECTURES**

**Session Chair: Ramon E. Parsons**, Icahn School of Medicine at Mount Sinai, New York, NY

6:00 p.m.-6:45 p.m.

**Molecular diversity of human breast cancer: Biologic and therapeutic implications**

Dennis J. Slamon, UCLA David Geffen School of Medicine, Los Angeles, CA

6:45 p.m.-7:30 p.m.

**Mapping stem and progenitor cells to decipher the origins of breast cancer**

Jane E. Visvader, Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

7:30 p.m.-9:30 p.m.

**OPENING RECEPTION**

## Sunday, October 8

7:30 a.m.-5:30 p.m.

**REGISTRATION**

7:30 a.m.-8:30 a.m.

**CONTINENTAL BREAKFAST**

8:30 a.m.-10:30 a.m.

**PLENARY SESSION 1: METABOLISM AND BREAST CANCER**

**Session Chair: Ramon E. Parsons**, Icahn School of Medicine at Mount Sinai, New York, NY

8:30 a.m.-9:00 a.m.

**Increased dependence on glutamine in PTEN-deficient breast cancer**

Ramon E. Parsons

9:00 a.m.-9:30 a.m.

**PI 3-Kinase and breast cancer**

Lewis C. Cantley, Weill Cornell Medical College, New York- Presbyterian Hospital, New York, NY

9:30 a.m.-10:00 a.m.

**Novel PARP-inhibitor combinations to treat breast cancer**

Gerburg M. Wulf, Beth Israel Deaconess Medical Center, Boston, MA

10:00 a.m.-10:30 a.m.

**Redefining druggability using chemoproteomic platforms for cancer therapy**

Daniel Nomura, University of California, Berkeley, Berkeley, CA

# CONFERENCE PROGRAM

<b>10:30 a.m.-11:00 a.m.</b>	<b>BREAK</b>
<b>11:00 a.m.-1:00 p.m.</b>	<b>PLENARY SESSION 2: FUNCTIONAL VALIDATION OF DRIVER MUTATIONS / INTERACTION MAPPING</b> <b>Session Chair: Ramon E. Parsons</b> , Icahn School of Medicine at Mount Sinai, New York, NY
11:00 a.m.-11:30 a.m.	<b>Title to be announced</b> Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
11:30 a.m.-12:00 p.m.	<b>From systems to structure: Bridging network and mechanism</b> Nevan J. Krogan, University of California, San Francisco, San Francisco, CA
12:00 p.m.-12:30 p.m.	<b>Title to be announced</b> José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY
12:30 p.m.-1:00 p.m.	<b>Targeting RNA metabolism in TNBC: From genetic networks to therapeutic opportunities</b> Thomas F. (Trey) Westbrook, Baylor College of Medicine, Houston, TX
<b>1:15 p.m.-3:45 p.m.</b>	<b>POSTER SESSION A / LUNCH</b>
<b>4:00 p.m.-6:00 p.m.</b>	<b>PLENARY SESSION 3: EXTRINSIC REGULATION OF BREAST CANCER DIVERSITY</b> <b>Session Chair: Laura J. van 't Veer</b> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
4:00 p.m.-4:30 p.m.	<b>Distinct immune microenvironments stratify triple negative breast cancer</b> Morag Park, McGill University Goodman Cancer Center, Montréal, QC, Canada
4:30 p.m.-5:00 p.m.	<b>Precision medicine for triple-negative breast cancer patients using a systems biology approach</b> Charles M. Perou, University of North Carolina, Chapel Hill, NC
5:00 p.m.-5:30 p.m.	<b>Extrinsic control of the breast cancer spectrum</b> Mary-Helen Barcellos-Hoff, University of California, San Francisco, San Francisco, CA
5:30 p.m.-6:00 p.m.	<b>Breast tumor evolution: The role of the microenvironment</b> Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
<b>6:00 p.m.</b>	<b>EVENING OFF / DINNER ON OWN</b>

# CONFERENCE PROGRAM

## Monday, October 9

7:30 a.m.-5:30 p.m.	<b>REGISTRATION</b>
7:30 a.m.-8:30 a.m.	<b>CONTINENTAL BREAKFAST</b>
8:30 a.m.-10:00 a.m.	<b>PLENARY SESSION 4: DNA DAMAGE</b> <b>Session Chair: Myles Brown</b> , Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA
8:30 a.m.-9:00 a.m.	<b>PARP inhibitor resistance and acquired vulnerability in breast cancer</b> Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA
9:00 a.m.-9:30 a.m.	<b>Title to be announced</b> Samuel Aparicio, BC Cancer Research Center, Vancouver, BC, Canada
9:30 a.m.-10:00 a.m.	<b>Precision medicine with therapies targeting defective DNA repair</b> Nicholas C. Turner, Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom
10:00 a.m.-10:30 a.m.	<b>BREAK</b>
10:30 a.m.-11:30 a.m.	<b>SPOTLIGHT SESSION: SHORT TALKS FROM PROFFERED PAPERS</b> <b>Session Chair: Laura J. van 't Veer</b> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
10:30 a.m.-10:42 a.m.	<b>Bcl11b maintains the long-term mammary stem cell and is crucial for drug resistance in breast cancer</b> Shang Cai, Stanford University, Palo Alto, CA
10:42 a.m.-10:54 a.m.	<b>Minor clones can drive polyclonal metastasis by affecting immune microenvironment</b> Michalina Janiszewska, Dana-Farber Cancer Institute, Boston, MA
10:54 a.m.-11:06 a.m.	<b>Neoadjuvant chemotherapy promotes macrophage-induced Mena<sup>INV</sup>-dependent prometastatic changes in breast tumors</b> George S. Karagiannis, Albert Einstein College of Medicine, Bronx, NY
11:06 a.m.-11:18 a.m.	<b>Differentiation dynamics of the developing mammary gland revealed by single-cell RNA-sequencing</b> Karsten Bach, University of Cambridge, Cambridge, United Kingdom
11:18 a.m.-11:30 a.m.	<b>The kinome of chemotherapy-resistant TNBC and identification of targetable kinases</b> Carolien Leonie Van Der Borden, University of California, San Francisco, San Francisco, CA

# CONFERENCE PROGRAM

<b>11:45 a.m.-1:15 p.m.</b>	<b>PLENARY SESSION 5: PERSONALIZED RISK</b> <b>Session Chair: Laura J. van 't Veer</b> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
11:45 a.m.-12:15 p.m.	<b>Personalized risk assessment to improve health care outcomes</b> Laura J. van 't Veer
12:15 p.m.-12:45 p.m.	<b>Homologous recombination repair deficiency and breast cancer progression in high-risk populations</b> Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL
12:45-1:15	<b>A coding region variant in the TP53 tumor-suppressor gene may underlie cancer disparities in African Americans</b> Maureen E. Murphy, The Wistar Institute, Philadelphia, PA
<b>1:15 p.m.-3:00 p.m.</b>	<b>FREE TIME / LUNCH ON OWN</b>
<b>3:00 p.m.-5:00 p.m.</b>	<b>PLENARY SESSION 6: MECHANISMS OF RESISTANCE TO TARGETED THERAPY</b> <b>Session Chair: Myles Brown</b> , Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA
3:00 p.m.-3:30 p.m.	<b>CDK 4/6 inhibitors: Moving beyond ER in ER+ breast cancer</b> Richard S. Finn, David Geffen School of Medicine at UCLA, Los Angeles, CA
3:30 p.m.-4:00 p.m.	<b>Overcoming therapeutic resistance by integrating targeted and immunotherapy: Insights from mouse models of human cancer</b> Jean J. Zhao, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
4:00 p.m.-4:30 p.m.	<b>Enhancer remodeling in response to MEK inhibition in TNBC</b> Gary L. Johnson, University of North Carolina School of Medicine, Chapel Hill, NC
4:30 p.m.-5:00 p.m.	<b>Drivers of endocrine resistance and synthetic lethal vulnerabilities in ER+ breast cancer</b> Myles Brown
<b>5:15 p.m.-7:45 p.m.</b>	<b>POSTER SESSION B / RECEPTION</b>

# CONFERENCE PROGRAM

## Tuesday, October 10

- 7:30 a.m.-12:30 p.m.                    REGISTRATION**
- 7:30 a.m.-8:30 a.m.                    CONTINENTAL BREAKFAST**
- 8:30 a.m.-10:00 a.m.                    PLENARY SESSION 7: EARLY CLINICAL OPPORTUNITIES**  
**Session Chair: Tak W. Mak**, University of Toronto Health Network / Princess Margaret Hospital, Toronto, ON, Canada
- 8:30 a.m.-9:00 a.m.                    **Title to be announced**  
Tak W. Mak
- 9:00 a.m.-9:30 a.m.                    **Clinical development of PI3K/AKT pathway inhibitors in breast cancer**  
Mika Derynck, Genentech, Inc., South San Francisco, CA
- 9:30 a.m.-10:00 a.m.                    **Developmental therapeutics in TNBC**  
Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX
- 10:00 a.m.-10:15 a.m.                    BREAK**
- 10:15 a.m.-11:45 a.m.                    PLENARY SESSION 8: WHAT LIMITS THE RESPONSE OF BREAST CANCER TO IMMUNOTHERAPY?**  
**Session Chair: Tak W. Mak**, University of Toronto Health Network / Princess Margaret Hospital, Toronto, ON, Canada
- 10:15 a.m.-10:45 a.m.                    **What resistance to PD-1 blockade in melanoma can tell us for breast cancer**  
Antoni Ribas, UCLA Medical Center, Los Angeles, CA
- 10:45 a.m.-11:15 a.m.                    **Setting the stage for immunotherapy in breast cancer: Where are we and where are we going in the clinic?**  
Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
- 11:15 a.m.-11:45 a.m.                    **What limits the response of breast cancer to immunotherapy?**  
Sherene Loi, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia

### DEPARTURE